Status:

COMPLETED

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Lead Sponsor:

Mesoblast, Inc.

Conditions:

Crohn's Disease

Eligibility:

All Genders

18-70 years

Phase:

PHASE3

Brief Summary

To provide open-label re-treatment with PROCHYMAL to subjects enrolled in companion Protocol 603 to evaluate the safety in subjects with active Crohn's disease who are resistant to standard Crohn's di...

Detailed Description

Subjects will receive infusions of PROCHYMAL on Day 42, Day 84, and Day 126 after initial infusion of PROCHYMAL in Protocol 603. Each infusion will contain 200 million cells. As subjects will be requi...

Eligibility Criteria

Inclusion

  • Subject must have qualified for, enrolled in, and provided written informed consent form (ICF) and authorization for use and disclosure of protected health information (PHI) for Protocol 603 after the August 3, 2010.
  • Subject successfully completed all screening assessments in Protocol 603 as required by Protocol 603.
  • Subject successfully completed the full course of each of the four infusions of investigational agent on Days 0, 3, 7, and 14 of Protocol 603 after August 3, 2010.
  • Subject must enroll in Protocol 611 on or before the 45th day after first infusion in Protocol 603.
  • Subject must provide written ICF and authorization for use and disclosure of PHI for Protocol 611.

Exclusion

  • Subject is unwilling or unable to adhere to requirements of Protocol 611.
  • Subject had confirmed respiratory distress during a PROCHYMAL infusion in any prior PROCHYMAL study.
  • Subject had a serious adverse event in any previous PROCHYMAL study that was deemed by the principal investigator of that study to be possibly or probably related to PROCHYMAL and also that was within 48 h after a PROCHYMAL infusion.

Key Trial Info

Start Date :

November 29 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 15 2014

Estimated Enrollment :

73 Patients enrolled

Trial Details

Trial ID

NCT01233960

Start Date

November 29 2010

End Date

September 15 2014

Last Update

December 8 2021

Active Locations (20)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (20 locations)

1

University of California, San Francisco

San Francisco, California, United States, 94115

2

Clinical Research of West Florida

Clearwater, Florida, United States, 33765

3

Shafran Gastroenterology Center

Winter Park, Florida, United States, 32789

4

University of Chicago

Chicago, Illinois, United States, 60611

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease | DecenTrialz